2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Brain Neoplasms
6
Breast Neoplasms
4
Recurrence
2
Oligodendroglioma
2
Meningeal Carcinomatosis
2
Glioblastoma
2
Astrocytoma
2
Triple Negative Breast Neoplasms
1
Meningeal Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Trastuzumab
4
Capecitabine
4
tucatinib
3
fludarabine
2
Spinal Puncture
2
Radiotherapy
2
Nivolumab
2
Methotrexate
2
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
sapanisertib
1
pertuzumab
1
patritumab deruxtecan
1
paclitaxel-Angiopep-2 conjugate
1
omburtamab I-131
1
mafosfamide
1
gadopiclenol
1
gadobutrol
1
fludarabine phosphate
1
eribulin
1
avelumab
1
aldesleukin
1
WP 744
1
Topotecan
1
Temozolomide
1
Specimen Handling
1
Rituximab
1
Psychiatric Rehabilitation
1
Phlebotomy
1
Mesna
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningeal Neoplasms
×
paclitaxel-Angiopep-2 conjugate
×
Clear all
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled